+データを開く
-基本情報
登録情報 | データベース: EMDB / ID: EMD-4146 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
タイトル | Human 26S proteasome in complex with Oprozomibプロテアソーム | ||||||||||||
マップデータ | |||||||||||||
試料 |
| ||||||||||||
機能・相同性 | 機能・相同性情報 positive regulation of inclusion body assembly / Impaired BRCA2 translocation to the nucleus / Impaired BRCA2 binding to SEM1 (DSS1) / thyrotropin-releasing hormone receptor binding / modulation by host of viral transcription / 加水分解酵素; プロテアーゼ; ペプチド結合加水分解酵素; オメガペプチターゼ / proteasome accessory complex / 減数分裂 / purine ribonucleoside triphosphate binding / positive regulation of proteasomal protein catabolic process ...positive regulation of inclusion body assembly / Impaired BRCA2 translocation to the nucleus / Impaired BRCA2 binding to SEM1 (DSS1) / thyrotropin-releasing hormone receptor binding / modulation by host of viral transcription / 加水分解酵素; プロテアーゼ; ペプチド結合加水分解酵素; オメガペプチターゼ / proteasome accessory complex / 減数分裂 / purine ribonucleoside triphosphate binding / positive regulation of proteasomal protein catabolic process / metal-dependent deubiquitinase activity / proteasome regulatory particle / cytosolic proteasome complex / proteasome regulatory particle, lid subcomplex / proteasome-activating activity / proteasome regulatory particle, base subcomplex / protein K63-linked deubiquitination / negative regulation of programmed cell death / regulation of endopeptidase activity / Defective homologous recombination repair (HRR) due to BRCA1 loss of function / Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function / Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function / Homologous DNA Pairing and Strand Exchange / Regulation of ornithine decarboxylase (ODC) / Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) / proteasome core complex / Resolution of D-loop Structures through Holliday Junction Intermediates / Cross-presentation of soluble exogenous antigens (endosomes) / Somitogenesis / Impaired BRCA2 binding to RAD51 / K63-linked deubiquitinase activity / immune system process / myofibril / proteasome binding / regulation of protein catabolic process / proteasome storage granule / Presynaptic phase of homologous DNA pairing and strand exchange / blastocyst development / transcription factor binding / polyubiquitin modification-dependent protein binding / general transcription initiation factor binding / endopeptidase activator activity / NF-kappaB binding / proteasome assembly / positive regulation of RNA polymerase II transcription preinitiation complex assembly / proteasome endopeptidase complex / proteasome core complex, beta-subunit complex / proteasome core complex, alpha-subunit complex / threonine-type endopeptidase activity / regulation of proteasomal protein catabolic process / enzyme regulator activity / mRNA export from nucleus / : / 封入体 / SARS-CoV-1 targets host intracellular signalling and regulatory pathways / negative regulation of inflammatory response to antigenic stimulus / response to organonitrogen compound / proteasome complex / proteolysis involved in protein catabolic process / sarcomere / Regulation of activated PAK-2p34 by proteasome mediated degradation / ciliary basal body / N-glycan trimming in the ER and Calnexin/Calreticulin cycle / Autodegradation of Cdh1 by Cdh1:APC/C / APC/C:Cdc20 mediated degradation of Securin / Asymmetric localization of PCP proteins / SCF-beta-TrCP mediated degradation of Emi1 / NIK-->noncanonical NF-kB signaling / Ubiquitin-dependent degradation of Cyclin D / AUF1 (hnRNP D0) binds and destabilizes mRNA / TNFR2 non-canonical NF-kB pathway / Assembly of the pre-replicative complex / Vpu mediated degradation of CD4 / Degradation of DVL / proteasomal protein catabolic process / P-body / 細胞分化 / Ubiquitin Mediated Degradation of Phosphorylated Cdc25A / Dectin-1 mediated noncanonical NF-kB signaling / Hh mutants are degraded by ERAD / Cdc20:Phospho-APC/C mediated degradation of Cyclin A / Degradation of AXIN / Defective CFTR causes cystic fibrosis / Degradation of GLI1 by the proteasome / lipopolysaccharide binding / Activation of NF-kappaB in B cells / Hedgehog ligand biogenesis / Negative regulation of NOTCH4 signaling / G2/M Checkpoints / GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 / double-strand break repair via homologous recombination / Autodegradation of the E3 ubiquitin ligase COP1 / Vif-mediated degradation of APOBEC3G / Hedgehog 'on' state / Regulation of RUNX3 expression and activity / Degradation of GLI2 by the proteasome / GLI3 is processed to GLI3R by the proteasome / MAPK6/MAPK4 signaling / FBXL7 down-regulates AURKA during mitotic entry and in early mitosis / response to virus 類似検索 - 分子機能 | ||||||||||||
生物種 | Homo sapiens (ヒト) / Synthetic construct (人工物) / Human (ヒト) | ||||||||||||
手法 | 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.8 Å | ||||||||||||
データ登録者 | Haselbach D / Schrader J / Lambrecht F / Henneberg F / Chari A / Stark H | ||||||||||||
資金援助 | ドイツ, 3件
| ||||||||||||
引用 | ジャーナル: Nat Commun / 年: 2017 タイトル: Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs. 著者: David Haselbach / Jil Schrader / Felix Lambrecht / Fabian Henneberg / Ashwin Chari / Holger Stark / 要旨: The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic activity is essential for cellular homeostasis. Thus, it is an attractive target for the development of ...The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic activity is essential for cellular homeostasis. Thus, it is an attractive target for the development of chemotherapeutics. While the structural basis of core particle (CP) inhibitors is largely understood, their structural impact on the proteasome holoenzyme remains entirely elusive. Here, we determined the structure of the 26S proteasome with and without the inhibitor Oprozomib. Drug binding modifies the energy landscape of conformational motion in the proteasome regulatory particle (RP). Structurally, the energy barrier created by Oprozomib triggers a long-range allosteric regulation, resulting in the stabilization of a non-productive state. Thereby, the chemical drug-binding signal is converted, propagated and amplified into structural changes over a distance of more than 150 Å from the proteolytic site to the ubiquitin receptor Rpn10. The direct visualization of changes in conformational dynamics upon drug binding allows new ways to screen and develop future allosteric proteasome inhibitors. | ||||||||||||
履歴 |
|
-構造の表示
ムービー |
ムービービューア |
---|---|
構造ビューア | EMマップ: SurfViewMolmilJmol/JSmol |
添付画像 |
-ダウンロードとリンク
-EMDBアーカイブ
マップデータ | emd_4146.map.gz | 13.9 MB | EMDBマップデータ形式 | |
---|---|---|---|---|
ヘッダ (付随情報) | emd-4146-v30.xml emd-4146.xml | 56.6 KB 56.6 KB | 表示 表示 | EMDBヘッダ |
画像 | emd_4146.png | 150.4 KB | ||
アーカイブディレクトリ | http://ftp.pdbj.org/pub/emdb/structures/EMD-4146 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-4146 | HTTPS FTP |
-関連構造データ
関連構造データ | 5m32MC M: このマップから作成された原子モデル C: 同じ文献を引用 (文献) |
---|---|
類似構造データ | |
電子顕微鏡画像生データ | EMPIAR-10166 (タイトル: human 26S proteasome bound to the chemotherapeutic Oprozomib Data size: 100.5 Data #1: Particle stack of aligned, summed and dose weighted particle images from the human 26S proteasome bound to oprozomib. [picked particles - single frame - processed]) |
-リンク
EMDBのページ | EMDB (EBI/PDBe) / EMDataResource |
---|---|
「今月の分子」の関連する項目 |
-マップ
ファイル | ダウンロード / ファイル: emd_4146.map.gz / 形式: CCP4 / 大きさ: 144.7 MB / タイプ: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ボクセルのサイズ | X=Y=Z: 1.27 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
密度 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
対称性 | 空間群: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
詳細 | EMDB XML:
CCP4マップ ヘッダ情報:
|
-添付データ
-試料の構成要素
+全体 : human 26S proteasome in complex with oprozomib
+超分子 #1: human 26S proteasome in complex with oprozomib
+超分子 #2: human 26S proteasome
+超分子 #3: bound oprozomib
+分子 #1: Proteasome subunit alpha type-2
+分子 #2: Proteasome subunit alpha type-4
+分子 #3: Proteasome subunit alpha type-7
+分子 #4: Proteasome subunit alpha type-5
+分子 #5: Proteasome subunit alpha type-1
+分子 #6: Proteasome subunit alpha type-3
+分子 #7: Proteasome subunit alpha type-6
+分子 #8: Proteasome subunit beta type-7
+分子 #9: Proteasome subunit beta type-3
+分子 #10: Proteasome subunit beta type-2
+分子 #11: Proteasome subunit beta type-5
+分子 #12: Proteasome subunit beta type-1
+分子 #13: Proteasome subunit beta type-4
+分子 #14: Proteasome subunit beta type-6
+分子 #15: Proteasome subunit alpha type-7
+分子 #16: Proteasome subunit alpha type-1
+分子 #17: 26S protease regulatory subunit 7
+分子 #18: 26S protease regulatory subunit 4
+分子 #19: 26S protease regulatory subunit 6B
+分子 #20: 26S protease regulatory subunit 10B
+分子 #21: 26S protease regulatory subunit 6A
+分子 #22: 26S protease regulatory subunit 8
+分子 #23: 26S proteasome non-ATPase regulatory subunit 1
+分子 #24: 26S proteasome non-ATPase regulatory subunit 3
+分子 #25: 26S proteasome non-ATPase regulatory subunit 12
+分子 #26: 26S proteasome non-ATPase regulatory subunit 11
+分子 #27: 26S proteasome non-ATPase regulatory subunit 6
+分子 #28: 26S proteasome non-ATPase regulatory subunit 7
+分子 #29: 26S proteasome non-ATPase regulatory subunit 13
+分子 #30: 26S proteasome non-ATPase regulatory subunit 4
+分子 #31: 26S proteasome non-ATPase regulatory subunit 14
+分子 #32: 26S proteasome non-ATPase regulatory subunit 8
+分子 #33: 26S proteasome complex subunit SEM1
+分子 #34: bound Oprozomib
+分子 #35: ADENOSINE-5'-DIPHOSPHATE
-実験情報
-構造解析
手法 | クライオ電子顕微鏡法 |
---|---|
解析 | 単粒子再構成法 |
試料の集合状態 | particle |
-試料調製
緩衝液 | pH: 6.5 構成要素:
| ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
グリッド | モデル: Quantifoil / 材質: COPPER / メッシュ: 200 / 支持フィルム - #0 - Film type ID: 1 / 支持フィルム - #0 - 材質: CARBON / 支持フィルム - #0 - トポロジー: HOLEY / 支持フィルム - #1 - Film type ID: 2 / 支持フィルム - #1 - 材質: CARBON / 支持フィルム - #1 - トポロジー: CONTINUOUS | ||||||||||||||||||
凍結 | 凍結剤: ETHANE / チャンバー内湿度: 72 % / チャンバー内温度: 4 K / 装置: LEICA EM GP / 詳細: blot with sensor. |
-電子顕微鏡法
顕微鏡 | FEI TITAN KRIOS |
---|---|
電子線 | 加速電圧: 300 kV / 電子線源: FIELD EMISSION GUN |
電子光学系 | C2レンズ絞り径: 70.0 µm / 倍率(補正後): 110236 / 照射モード: SPOT SCAN / 撮影モード: BRIGHT FIELDBright-field microscopy / Cs: 0.0001 mm / 最大 デフォーカス(公称値): 8.4 µm / 最小 デフォーカス(公称値): 0.3 µm / 倍率(公称値): 59000 |
特殊光学系 | 球面収差補正装置: Microscope is equipped with Cs corrector |
試料ステージ | 試料ホルダーモデル: FEI TITAN KRIOS AUTOGRID HOLDER ホルダー冷却材: NITROGEN |
撮影 | フィルム・検出器のモデル: FEI FALCON II (4k x 4k) 検出モード: OTHER / デジタル化 - サイズ - 横: 4096 pixel / デジタル化 - サイズ - 縦: 4096 pixel / デジタル化 - サンプリング間隔: 14.0 µm / 撮影したグリッド数: 1 / 平均露光時間: 1.0 sec. / 平均電子線量: 2.0 e/Å2 |
実験機器 | モデル: Titan Krios / 画像提供: FEI Company |
-画像解析
CTF補正 | ソフトウェア - 名称: Gctf |
---|---|
初期 角度割当 | タイプ: OTHER / ソフトウェア - 名称: SIMPLE (ver. 2) / ソフトウェア - 詳細: PRIME |
最終 3次元分類 | ソフトウェア - 名称: RELION (ver. 1.4) |
最終 角度割当 | タイプ: PROJECTION MATCHING / ソフトウェア - 名称: RELION (ver. 2) / ソフトウェア - 詳細: beta |
最終 再構成 | 想定した対称性 - 点群: C1 (非対称) / アルゴリズム: FOURIER SPACE / 解像度のタイプ: BY AUTHOR / 解像度: 3.8 Å / 解像度の算出法: FSC 0.143 CUT-OFF / ソフトウェア - 名称: RELION (ver. 2) / ソフトウェア - 詳細: beta / 使用した粒子像数: 233000 |